- জেনেরিক নাম
- Palonosetron
- শক্তি
- .075 mg/1.5 ml
- ডোজ ফর্ম
- Injection
- প্রস্তুতকারক
- Orion Pharma Ltd.
Palostar 0.075 Injection
Palostar 0.075 .075 mg/1.5 ml Injection সম্পর্কে
Palostar 0.075 হলো Palonosetron-এর একটি ব্র্যান্ড, শক্তি .০৭৫ mg/১.৫ ml, ইনজেকশন আকারে। Palostar 0.075-এর সাথে Palonosetron-এর অন্য ব্র্যান্ডের দাম নিচে তুলনা করে দেখুন। Palostar 0.075 প্রস্তুত করেছে Orion Pharma Ltd। ডাক্তারের প্রেসক্রিপশন মেনে চলুন এবং অন্য ব্র্যান্ড খাওয়া যাবে কি না তা ফার্মাসিস্টের কাছ থেকে জেনে নিন।
Palonosetron-এর ১৬টি ব্র্যান্ড বাংলাদেশে তালিকাভুক্ত।
Palostar 0.075 .075 mg/1.5 ml Injection কী?
The injection Palostar 0.075 contains Palonosetron and is made by Orion Pharma Ltd. It is used to prevent and treat nausea and vomiting that can happen after chemotherapy, radiotherapy, or surgery. It is commonly given in connection with treatments such as chemotherapy or radiotherapy, and may also be used for nausea and vomiting after surgery. Ask your doctor or pharmacist if you are unsure about it.
Palostar 0.075-এর ব্যবহার
It may also be used for nausea and vomiting that is not well controlled, and for nausea and vomiting after surgery. It may be used for radiotherapy-related nausea as well. It is an anti-emetic, a medicine that acts against vomiting. Your doctor will decide if it is right for your situation.
Palostar 0.075 কীভাবে ব্যবহার করবেন
If you have questions about your dose or schedule, ask your healthcare team. Palostar 0.075 is given as an injection by a healthcare professional. Do not inject it yourself unless a doctor has shown you how. Do not take extra injections to make up for a missed one. Do not change the dose or stop early without asking your doctor. Always follow the instructions of your doctor or nurse.
Palostar 0.075-এর পার্শ্বপ্রতিক্রিয়া
If you notice any side effect that worries you, or if it does not settle, tell your doctor or pharmacist. Not everyone who receives the injection will have these effects. Your healthcare team can advise on what to do and whether any further care is needed. Tell your doctor if these bother you or do not settle.
সতর্কতা ও নিরাপত্তা
Store in a cool, dry place away from light. Before treatment, tell your doctor about all your medical conditions and medicines. Do not receive Palostar 0.075 if you are allergic to Palonosetron or any ingredient in the injection. Ask your doctor first if any of these apply to you.
সাধারণ প্রশ্ন
What does Palostar 0.075 treat?
It may also be used for nausea and vomiting that is not well controlled, and for nausea and vomiting after surgery. It may be used for radiotherapy-related nausea as well.
How is Palostar 0.075 used?
If you have questions about your dose or schedule, ask your healthcare team. Palostar 0.075 is given as an injection by a healthcare professional.
Can Palostar 0.075 cause side effects?
If you notice any side effect that worries you, or if it does not settle, tell your doctor or pharmacist. Not everyone who receives the injection will have these effects.
Who should be careful with Palostar 0.075?
Store in a cool, dry place away from light. Before treatment, tell your doctor about all your medical conditions and medicines.
নির্দেশনা
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Palonosetron indicated in-- Acute and delayed nausea and vomiting
- Uncontrolled nausea and vomiting
- Chemotherapy-induced nausea and vomiting (CINV): Acute CINV resulting in on the day of treatment with certain types of chemotherapy
- Delayed CINV resulting in on days later with certain types of chemotherapy ... Read more
- Acute and delayed nausea and vomiting
- Uncontrolled nausea and vomiting
- Chemotherapy-induced nausea and vomiting (CINV): Acute CINV resulting in on the day of treatment with certain types of chemotherapy
- Delayed CINV resulting in on days later with certain types of chemotherapy
- Radiotherapy-induced nausea and vomiting (RINV)
- Post-operative & Post-discharge nausea and vomiting (PONV & PDNV).
ফার্মাকোলজি
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Palonosetron is a 5-HT3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine and that the released serotonin then activates 5-HT3 receptors that are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema, to initiate the vomiting reflex. Postoperative nausea and vomiting is influenced by multiple patient, surgical and anesthesia related factorcs and is triggered by release of 5-HT3 in a cascade of neuronal event involving both the central nervous system and the gastrointestinal tract. The 5-HT3 receptor has been demonstrated to selectively participate in the emetic response. Palonosetron works by blocking the actions of Serotonin, associated with nausea and vomiting, at 5-HTs receptor. It is likely that Palonosetron works in the small intestine but it may also work in the brain.Pharmacokinetics: Palonosetron exhibits linear dose-proportional pharmacokinetics over the doserange 1-90 pg/kg in healthy subjects and in patients with cancer. In cancer patients receiving single intravenous doses of Palonosetron in this dose range, the mean maximum plasma concentration (Cmax) ranges from 0.89 to 336 ng/ml and the area under the plasma concentration-time curve from zero to infinity (AUCo-co) ranges from 13.8 to 957 ng.h/ml. Palonosetron has a volume of distribution of approximately 6.9-7.9 L/kg, with approximately 62% bound to plasma proteins. Approximately 50% of Palonosetron is metabolized into two inactive metabolites that exhibit <1% of the 5-HT3 receptor antagonist activity. Approximately 40% of the drug is metabolised via kidney, 50% by liver CYP2D6 (mainly), CYP3A4 and CYP1A2 isoenzymes. About 50% of the drug goes under metabolism. After a single intravenous dose, approximately 40% is excreted as unchanged drug in the urine after 144 hours. Total body clearance of Palonosetron is 160±35 ml/h/kg, and renal clearance is 66.5±18.2 ml/h/kg in healthy subjects. Palonosetron exhibits a longer half-life (40 hours) and has a greater 5-HT3 receptor binding affinity.
মাত্রা ও সেবনবিধি
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Usual dosage: Adult tablet dosage: 0.5 mg daily. Adult IV dosage: A single IV dose of 0.075 mg should be administered over 10 seconds.Chemotherapy-induced nausea and vomiting: Adult tablet dosage: 0.5 mg administered approximately 1 hour prior to the start of chemotherapy. Adult IV dosage: A single IV dose of 0.25 mg should be administered over 30 seconds approximately 30 minutes before the start of chemotherapy.
Radiotherapy-induced nausea and vomiting: A single IV dose of 0.25 mg should be administered over 30 seconds approximately 30 minutes before each week of radiation fraction.
Post-operative nausea and vomiting: A single IV dose of 0.075 mg should be administered over 10 seconds immediately before induction of anesthesia.
Children dosage: (1 month to 17 years): A single IV dose at 20 mcg/kg body weight. Which maximum dose is 1.5 mg.
ঔষধের মিথষ্ক্রিয়া
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
In controlled clinical trials, Palonosetron injection has been safely administered with corticosteroids, analgesics, antiemetics/antinauseants, antispasmodics and anticholinergic agents. Palonosetron did not inhibit the antitumor activity of cisplatin, cyclophosphamide, cytarabine, doxorubicin and mitomycin C in murine tumor models. Concomitant administration of Palonosetron and metoclopramide has no significant pharmacokinetic interactions. In vitro studies indicated that palonosetron is not inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1 & CYP3A4/5 (CYP2C19 was not investigated) nor does it induce the activity of CYP1A2, CYP2D6 or CYP3A4/5. Therefore, the potential for clinically significant drug interactions with Palonosetron appears to be low.প্রতিনির্দেশনা
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Palonosetron is contraindicated in patients known to have hypersensitivity to the drug or any of its components.পার্শ্ব প্রতিক্রিয়া
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
The most common adverse reactions are headaches and constipation.গর্ভাবস্থায় ও স্তন্যদানকালে
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Pregnancy category 'B'. It is not known whether Palonosetron is excreted in breast milk.মাত্রাধিক্যতা
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
There is no known antidote to Palonosetron. Overdose should be managed with supportive care.সংরক্ষণ
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Store in a cool & dry place, protected from light.বিকল্প ব্র্যান্ড: Palonosetron
একই জেনেরিকের অন্য ব্র্যান্ড, কম দাম আগে।
ঔষধের তথ্য শুধু জানার জন্য, এটি চিকিৎসা পরামর্শ নয়। সবসময় ডাক্তারের প্রেসক্রিপশন মানুন এবং ফার্মাসিস্টের সাথে কথা বলুন।